The primary treatment modality for ovarian cancer is radical surgery. Rates of post-operative morbidity (20-30%) and hospital readmission (10-15%) are high. Low QOL prior to chemotherapy (i.e. after surgery) is associated with delayed chemotherapy start, dose delays, and decreased overall survival. The quality of surgical recovery in this population is high-stakes, with an impact … Read more